Physician profile
Samad Zaheeruddin
NPI 1295091767
$17,066.04
in general payments reported to CMS, 2019-2025
30 companies · $2,830 in 2025
The $2,830 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,053 · 2020: $130 · 2021: $183 · 2022: $6,076 · 2023: $2,792 · 2024: $2,002 · 2025: $2,830.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,757 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,458 · Honoraria: $1,450 · Travel and Lodging: $960.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,756.64 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,458.00 |
| Honoraria | $1,450.00 |
| Travel and Lodging | $959.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Chiesi USA, INC. | $9,753.77 | 2020-2025 | Kengreal, Cleviprex |
| Edwards Lifesciences Corporation | $2,604.77 | 2019-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Sapien 3 Ultra Resilia |
| Abbott Laboratories | $1,836.78 | 2019-2025 | Esprit, Pressurewire, Diamondback Coronary |
| Abiomed | $457.98 | 2019-2025 | Impella |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $335.45 | 2022-2025 | Lifevest |
| Boston Scientific Corporation | $298.68 | 2021-2025 | Opticross, Avvigo Guidance System, Watchman Access System |
| Philips North America LLC | $282.19 | 2023-2024 | (5044) Mcot |
| Medtronic Vascular, INC. | $254.93 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $226.96 | 2020-2023 | Brilinta |
| Penumbra, INC. | $188.62 | 2020-2024 | Indigo System, Penumbra System |
| Medtronic, INC. | $173.71 | 2021-2023 | Micra |
| Amgen INC. | $122.61 | 2019-2025 | Repatha, Repatha |
| W. L. Gore & Associates, INC. | $103.54 | 2019 | |
| Novartis Pharmaceuticals Corporation | $50.52 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $44.55 | 2024-2025 | Verquvo |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $38.57 | 2023-2025 | Camzyos |
| Inari Medical, INC. | $36.97 | 2021 | |
| Cardiva Medical, INC. | $33.67 | 2023-2025 | Optowire, Cardiva Vascade Mvp Vvcs 6-12f |
| Janssen Pharmaceuticals, INC | $28.25 | 2019-2022 | |
| Pfizer INC. | $27.51 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.70 | 2025 | Jardiance |
| Novo Nordisk INC | $20.65 | 2025 | Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $20.24 | 2025 | |
| Shockwave Medical, INC | $18.24 | 2019 | |
| Sanofi-Aventis U.S. LLC | $15.57 | 2022 | |
| Heartflow, INC. | $15.42 | 2024 | |
| Azurity Pharmaceuticals, INC. | $14.20 | 2024 | Edarbyclor |
| B. Braun Interventional Systems INC. | $13.98 | 2019 | |
| Kiniksa Pharmaceuticals, LTD. | $13.65 | 2023 | Arcalyst |
| Kiniksa Pharmaceuticals International, Plc | $13.36 | 2024 | Arcalyst |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samad Zaheeruddin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.